![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EC Gives Marketing Authorization to Hepatitis Drug Olysio
EC Gives Marketing Authorization to Hepatitis Drug Olysio
![](https://www.fdanews.com/ext/resources/test/Drug-Images/petridishwithredliquid.gif?t=1434089270&width=250)
The European Commission has given marketing authorization to Olysio (simeprevir) for the treatment of adults with hepatitis C (HCV) genotype 1 and 4 infection, its drugmaker Janssen-Cilag said.
Depending on the patient’s condition, Olysio provides a triple treatment option, to be used as part of a combination therapy with sofosbuvir or pegylated interferon (PegIFN) and with or without ribavirin (RBV), the company said.
Conditions and necessary combinations are as follows:
- Patients with HCV genotype 1 or 4, who are intolerant or ineligible for interferon treatment and regardless of prior treatment, should take simpervir and sofosbuvir, with or without RBV for 12 weeks.
- Treatment-naïve and prior relapse patients with genotype 1 or 4, with or without cirrhosis and those co-infected with HIV should take simeprevir, PegIFN and RBV together for 24 weeks.
- Prior non-responder patients (including partial and null responders) with genotype 1 or 4 and those co-infected with HIV should take simeprevir, PegIFN and RBV together for 48 weeks.
The company said Japan approved simeprevir for the treatment of genotype 1 HCV in March 2013. It was approved for the same treatment by the Canada and the U.S. in September and November, 2013, respectively. — Kellen Owings
Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.
Upcoming Events
-
21Oct